Back to search results
NCT05284513

Collaborative Approach to Reach Everyone With Familial Hypercholesterolemia (CARE-FH)

Enrolling by Invitation
NAAges 26+Interventional
Geisinger Clinic
~532 participants
Updated 2025-12-22 on ClinicalTrials.gov
What's tested:FH diagnosis programImplementation strategy package: Develop and implement tools for quality monitoringImplementation strategy package: Develop educational materialsImplementation strategy package: Conduct educational outreach visitsImplementation strategy package: Intervene with clinicians and patients to enhanceBehavioral (e.g., Psychotherapy, Lifestyle Counseling) Implementation strategy package: Identify and prepare champions Clinical lipid champions

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
FH diagnosis rate (Aim 2)
Measured over Up to 45 months
+2 more outcomes measured

Conditions

Familial Hypercholesterolemia

Explore related trials

Hyperlipoproteinemia, Type IIa

Where it's being run

1 sites across 1 states
Pennsylvania1

Study leadership

  • Laney K Jones, PharmD, MPH · PRINCIPAL_INVESTIGATOR · Geisinger Clinic
  • Samuel S Gidding, MD · PRINCIPAL_INVESTIGATOR · Geisinger Clinic

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Primary care clinicians (pediatrician, community medicine, internal medicine) in the Geisinger Healthcare System

Exclusion

None

What this trial measures

  • FH diagnosis rate (Aim 2)Up to 45 months

    FH diagnosis rate, is achieving both the scheduling of a clinic visit and evidence the clinician, at that visit, has completed evidence-based FH diagnostic evaluation, defined as completing one of: using the FH clinic note to document care, adding FH diagnosis on the problem list, using the FH smart-set (or ordered a genetic test for FH), making a referral to the lipid clinic, or starting a statin for an evidence-based indication

  • Acceptability (Aim 3)Month 9, 12, 18, 24, 30, 36, 42

    Clinician and patient satisfaction and self-efficacy with the FH diagnosis program

  • Timeliness (Aim 4)Up to 45 months

    Time to FH screen, time to diagnostic evaluation, time to statin initiation